GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Cash from Financing Activities data on file, last reported at $38.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $38.6 million, up 181.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.9 million (up 25.0% YoY), and the FY2025 annual result was $48.0 million, up 8.75% from the prior year.
• Cash from Financing Activities advanced to $38.6 million in Q1 2026 per WGS's latest filing, from $23.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $198.1 million in Q2 2022 and troughed at -$911000.0 in Q3 2023.
• A 5-year average of $30.3 million and a median of $10.8 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 83011.25% in 2023, then plunged 105.29% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $65000.0 in 2022, then surged by 72366.15% to $47.1 million in 2023, then slumped by 34.14% to $31.0 million in 2024, then declined by 25.24% to $23.2 million in 2025, then jumped by 66.39% to $38.6 million in 2026.
• Business Quant data shows WGS's Cash from Financing Activities at $38.6 million in Q1 2026, $23.2 million in Q4 2025, and $10.8 million in Q3 2025.